CoChat

AAV gene therapy for Tay-Sachs disease

Open access

Published version of a preprint

The DOI matches its Crossref record; 44 of the 45 references it cites were found in a registry or an index.

Abstract

Tay-Sachs disease (TSD) is an inherited neurological disorder caused by deficiency of hexosaminidase A (HexA). Here, we describe an adeno-associated virus (AAV) gene therapy expanded-access trial in two patients with infantile TSD (IND 18225) with safety as the primary endpoint and no secondary endpoints. Patient TSD-001 was treated at 30 months with an equimolar mix of AAVrh8-HEXA and AAVrh8-HEXB administered intrathecally (i.t.), with 75% of the total dose (1 × 10 14 vector genomes (vg)) in the cisterna magna and 25% at the thoracolumbar junction. Patient TSD-002 was treated at 7 months by combined bilateral thalamic (1.5 × 10 12 vg per thalamus) and i.t. infusion (3.9 × 10 13 vg). Both patients were immunosuppressed. Injection procedures were well tolerated, with no vector-related adverse events (AEs) to date. Cerebrospinal fluid (CSF) HexA activity increased from baseline and remained stable in both patients. TSD-002 showed disease stabilization by 3 months after injection with ongoing myelination, a temporary deviation from the natural history of infantile TSD, but disease progression was evident at 6 months after treatment. TSD-001 remains seizure-free at 5 years of age on the same anticonvulsant therapy as before therapy. TSD-002 developed anticonvulsant-responsive seizures at 2 years of age. This study provides early safety and proof-of-concept data in humans for treatment of patients with TSD by AAV gene therapy.

Overview

Integrity signals

Registry

Crossref · 10.1038/s41591-021-01664-4

Cites

44 of 44 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 44 references

Research works printed but not linked: 1

  1. Taghian, T. et al. A safe and reliable technique for CNS delivery of AAV vectors in the cisterna magna. Mol. Ther. 28, 411–421 (2020). · DOI

Cited by

See all 149

Metadata

Authors
Flotte, T. R., Cataltepe, O., Puri, A., Batista, A. R., Moser, R., McKenna-Yasek, D., Douthwright, C., Gernoux, G., Blackwood, M., Mueller, C., Tai, P. W. L., Jiang, X., Bateman, S., Spanakis, S. G., Parzych, J., Keeler, A. M., Abayazeed, A., Rohatgi, S., Gibson, L., Finberg, R., Barton, B. A., Vardar, Z., Shazeeb, M. S., Gounis, M., Tifft, C. J., Eichler, F. S., Brown, R. H., Martin, D. R., Gray-Edwards, H. L., & Sena-Esteves, M.
Affiliations
  • University of Massachusetts Chan Medical School (US)
  • Washington University in St. Louis (US)
  • National Institutes of Health (US)
  • Harvard University (US)
  • Auburn University (US)
Corresponding author
Flotte, Terence R.
Venue
Nature Medicine
Published
2022-02
Volume
28
Issue
2
Pages
251-259
ISSN
  • 1078-8956 (ISSN-L)
  • 1546-170X
OpenAlex
W4211164289
Cited by
143
References
45
Citations by year
2026: 26 · 2025: 29 · 2024: 36 · 2023: 34 · 2022: 18
FWCI
18.09
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Medicine (publishedVersion)
  • Research Square (acceptedVersion, cc-by)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
  • The Journal of the American Medical Association (JAMA) Network (American Medical Association) (submittedVersion)
Funders
BlueGenes Foundation
Topics
  • Health Sciences › Medicine › Genetics (clinical) › Lysosomal Storage Disorders Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
  • Health Sciences › Medicine › Genetics (clinical) › Neurogenetic and Muscular Disorders Research
Keywords
Tay-Sachs disease, AAV gene therapy, hexosaminidase A, hexosaminidase B, intrathecal gene delivery, cisterna magna, immunosuppression, stable disease, seizure control, feasibility and safety
MeSH terms
Dependovirus, Anticonvulsants, Humans, Tay-Sachs Disease, Genetic Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: AAV gene therapy for Tay-Sachs disease. https://app.cochat.ai/papers/10.1038/s41591-021-01664-4
The paper
Flotte, T. R., Cataltepe, O., Puri, A., Batista, A. R., Moser, R., McKenna-Yasek, D., Douthwright, C., Gernoux, G., Blackwood, M., Mueller, C., Tai, P. W. L., Jiang, X., Bateman, S., Spanakis, S. G., Parzych, J., Keeler, A. M., Abayazeed, A., Rohatgi, S., Gibson, L., . . . Sena-Esteves, M. (2022). AAV gene therapy for Tay-Sachs disease. Nature Medicine. https://doi.org/10.1038/s41591-021-01664-4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.